These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36704237)

  • 1. Antihypertensive Effects of Esaxerenone in Older Patients with Primary Aldosteronism.
    Fujimoto M; Watanabe S; Igarashi K; Ruike Y; Ishiwata K; Naito K; Ishida A; Koshizaka M; Suzuki S; Shiko Y; Koide H; Yokote K
    Int J Hypertens; 2023; 2023():6453933. PubMed ID: 36704237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.
    Yoshida Y; Fujiwara M; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Iwamoto M; Mori Y; Nagai S; Matsuda N; Noguchi T; Okamoto M; Gotoh K; Masaki T; Shibata H
    Hypertens Res; 2024 Jan; 47(1):157-167. PubMed ID: 37717115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study.
    Uchida HA; Nakajima H; Hashimoto M; Nakamura A; Nunoue T; Murakami K; Hosoya T; Komoto K; Taguchi T; Akasaka T; Shiosakai K; Sugimoto K; Wada J;
    Adv Ther; 2022 Nov; 39(11):5158-5175. PubMed ID: 36070133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated with the Antihypertensive Effect of Esaxerenone and Serum Potassium Elevation: A Pooled Analysis of Seven Phase III Studies.
    Ito S; Okuda Y; Sugimoto K
    Adv Ther; 2023 Mar; 40(3):1242-1266. PubMed ID: 36662393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetes Mellitus Undergoing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors (EAGLE-DH).
    Motoki H; Inobe Y; Fukui T; Iwasaki A; Hiramitsu S; Koyama S; Masuda I; Sekimura N; Yamamoto K; Sato A; Komatsu M; Taguchi T; Shiosakai K; Sugimoto K; Kuwahara K
    Adv Ther; 2023 Nov; 40(11):5055-5075. PubMed ID: 37733211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing the efficacy and safety of esaxerenone in hypertensive patients: a pooled analysis of five clinical studies on different comorbidities.
    Kario K; Katsuya T; Wada J; Motoki H; Kuwahara K; Tsujita K; Taguchi T; Tanabe A; Shimosawa T
    Hypertens Res; 2024 Oct; 47(10):2826-2839. PubMed ID: 39090179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism.
    Satoh F; Ito S; Itoh H; Rakugi H; Shibata H; Ichihara A; Omura M; Takahashi K; Okuda Y; Iijima S
    Hypertens Res; 2021 Apr; 44(4):464-472. PubMed ID: 33199881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction.
    Ito S; Itoh H; Rakugi H; Okuda Y; Iijima S
    Hypertens Res; 2021 May; 44(5):489-497. PubMed ID: 33323991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
    Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
    Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study.
    Iwahana T; Saito Y; Okada S; Kato H; Ono R; Kobayashi Y
    PLoS One; 2021; 16(11):e0259485. PubMed ID: 34748605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study.
    Itoh H; Ito S; Rakugi H; Okuda Y; Nishioka S
    Hypertens Res; 2019 Oct; 42(10):1572-1581. PubMed ID: 31239535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect.
    Ichikawa S; Tsutsumi J; Sugimoto K; Yamakawa S
    Adv Ther; 2022 Oct; 39(10):4779-4791. PubMed ID: 35976603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Dosage of MRA Improves BP and Urinary Albumin Excretion in Primary Aldosteronism With Suppressed Plasma Renin.
    Saiki A; Otsuki M; Tamada D; Kitamura T; Mukai K; Yamamoto K; Shimomura I
    J Endocr Soc; 2022 Jan; 6(1):bvab174. PubMed ID: 34909517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.
    Ito S; Itoh H; Rakugi H; Okuda Y; Yamakawa S
    J Hum Hypertens; 2019 Jul; 33(7):542-551. PubMed ID: 31113987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
    Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
    Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
    Arai K; Morikawa Y; Ubukata N; Sugimoto K
    Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone.
    Oshima A; Imamura T; Narang N; Kinugawa K
    Circ Rep; 2021 May; 3(6):333-337. PubMed ID: 34136708
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies.
    Shikata K; Ito S; Kashihara N; Nangaku M; Wada T; Okuda Y; Sawanobori T; Sugimoto K
    J Diabetes Investig; 2022 Jul; 13(7):1190-1202. PubMed ID: 35199478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of a multicenter randomized study comparing the efficacy and safety of esaxerenone versus trichlormethiazide in patients with uncontrolled essential hypertension: EXCITE-HT study.
    Kario K; Ohishi M; Katsuya T; Taguchi T; Tanabe A; Sugimoto K; Shimosawa T
    J Clin Hypertens (Greenwich); 2023 Sep; 25(9):861-867. PubMed ID: 37551054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of biochemical tests and clinical symptoms in differential diagnosis of primary aldosteronism.
    Prejbisz A; Postuła M; Cybulska I; Dobrucki T; Kabat M; Peczkowska M; Janas J; Janaszek-Sitkowska H; Makowiecka-Cieśla M; Januszkiewicz A
    Kardiol Pol; 2003 Jan; 58(1):17-26. PubMed ID: 14502298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.